Jefferies Issues a Buy Rating on AveXis Inc

By Austin Angelo

In a report released yesterday, Biren Amin from Jefferies reiterated a Buy rating on AveXis Inc (NASDAQ: AVXS), with a price target of $92. The company’s shares closed yesterday at $75.31.

According to TipRanks.com, Amin is a 3-star analyst with an average return of 2.5% and a 47.8% success rate. Amin covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Lion Biotechnologies Inc, and Bellicum Pharmaceuticals.

AveXis Inc has an analyst consensus of Strong Buy, with a price target consensus of $98.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.